Cell therapy specialist AlloVir Inc. has gained a valuable PRIME status in Europe for its lead candidate, a novel T-cell therapy to treat viral infections in stem cell transplant patients.
The Houston, Texas-headquartered company is headed up by one-time Alexion Pharmaceuticals Inc. CEO David Hallal, who is also co-founder...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
